Delcath Systems, Inc. (NASDAQ: DCTH), a medical technology company specializing in cancer treatment, is currently testing a proprietary, patented drug delivery system designed to treat liver cancers. The company is enrolling patients in Phase III and Phase II clinical studies for the treatment of liver cancers using high doses of melphalan. Twenty-eight international patents consist of the Company’s intellectual property portfolio. For further information, visit the Company’s web site at www.delcath.com.
- 17 years ago
QualityStocks
Delcath Systems, Inc. (NASDAQ: DCTH)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Nicola Mining Inc. (TSX.V: NIM) (OTCQB: HUSIF) Advances Integrated Approach in Broader Growth Strategy
Nicola Mining (TSX.V: NIM) (OTCQB: HUSIF) recently took a significant step in fostering industry collaboration and…
-
MoneyShow Presents Real Estate Plays for Profit and Income Expo
MoneyShow has empowered individual investors and traders with state-of-the-art tools, education, and access to specific…
-
New Pacific Metals Corp. (NYSE American: NEWP) (TSX: NUAG) Eyes Bolivia’s Untapped Silver Potential Amid Global Supply Gaps
Bolivia, despite its rich mining history, remains one of the most underexplored silver jurisdictions due…